Beijing Sun-Novo Pharmaceutical Research 阳光诺和
23 significant filings since 28 May 2026: 2 on regulatory inquiry, 1 on litigation and 6 on equity incentive, and 6 other kinds. The latest, on 25 Sep 2026: 关于诉讼事项进展暨达成和解的公告.
自 28 May 2026 起有 23 份重大公告：regulatory inquiry 2 份、litigation 1 份、equity incentive 6 份，另有 6 类。最新一份（25 Sep 2026）：关于诉讼事项进展暨达成和解的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中银证券 | 刘恩阳,苏雪儿 | Buy 买入 | 7 Sep 2026 | 1 | — |
| 开源证券 | 余汝意,刘艺 | Buy 买入 | 28 Apr 2026 | 1 | — |
| 华安证券 | 谭国超,杨馥瑗 | Buy 买入 | 25 Dec 2025 | 2 | — |
| 太平洋 | 周豫,张崴 | Buy 买入 | 4 Nov 2025 | 1 | — |
| 华鑫证券 | 胡博新,吴景欢 | Buy 买入 | 28 Sep 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 6 reports. 每行为该券商近十二个月的最新研报；6 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。